Literature DB >> 20627200

Preliminary report: hyperhomocysteinemia in patients with acute intermittent porphyria.

Jordi To-Figueras1, Rosa Maria Lopez, Ramon Deulofeu, Carmen Herrero.   

Abstract

Homocysteine is an intermediate of methionine metabolism, and its elevation in tissues is correlated with an increased risk for vascular diseases. We measured homocysteine in plasma of 24 patients with acute intermittent porphyria (AIP) and long-term high excretion of heme precursors. Fifteen (62.5%) presented hyperhomocysteinemia (total homocysteine in plasma >15 μmol/L). No association was found between hyperhomocysteinemia and either urinary excretion of heme precursors or clinical status. All the patients showed normal levels of vitamin B₁₂ and folic acid, but 13 (54%) presented low plasma levels of pyridoxal 5'-phosphate (PLP <15 nmol/L). Cystathionine β-synthase (CBS) catalyzes a major removal pathway of homocysteine and is dependent on both PLP and heme as cofactors. It is hypothesized that, in AIP, CBS reduced hepatic activity resulting from either a low heme status and/or consumptive depletion of PLP due to increased demand by 5-aminolevulinatesynthase hyperactivity can induce hyperhomocysteinemia.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20627200     DOI: 10.1016/j.metabol.2010.05.016

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  9 in total

1.  Endothelial Dysfunction in Acute Hepatic Porphyrias.

Authors:  Andrea Ricci; Gilda Sandri; Matteo Marcacci; Elena Di Pierro; Francesca Granata; Chiara Cuoghi; Stefano Marchini; Antonello Pietrangelo; Paolo Ventura
Journal:  Diagnostics (Basel)       Date:  2022-05-24

2.  Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?

Authors:  Petro E Petrides; Michael Klein; Elfriede Schuhmann; Heike Torkler; Brigitte Molitor; Christian Loehr; Zahra Obermeier; Maria K Beykirch
Journal:  Ann Hematol       Date:  2021-05-29       Impact factor: 3.673

3.  Clinical, biochemical, and genetic characterization of acute hepatic porphyrias in a cohort of Argentine patients.

Authors:  María Del Carmen Martinez; Gabriela Nora Cerbino; Bárbara Xoana Granata; Alcira Batlle; Victoria Estela Parera; María Victoria Rossetti
Journal:  Mol Genet Genomic Med       Date:  2021-03-25       Impact factor: 2.183

4.  Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.

Authors:  Paolo Ventura; Herbert L Bonkovsky; Laurent Gouya; Paula Aguilera-Peiró; D Montgomery Bissell; Penelope E Stein; Manisha Balwani; D Karl E Anderson; Charles Parker; David J Kuter; Susana Monroy; Jeeyoung Oh; Bruce Ritchie; John J Ko; Zhaowei Hua; Marianne T Sweetser; Eliane Sardh
Journal:  Liver Int       Date:  2021-11-16       Impact factor: 8.754

Review 5.  Nutrients and Porphyria: An Intriguing Crosstalk.

Authors:  Elena Di Pierro; Francesca Granata
Journal:  Int J Mol Sci       Date:  2020-05-14       Impact factor: 5.923

Review 6.  Therapy Follows Diagnosis: Old and New Approaches for the Treatment of Acute Porphyrias, What We Know and What We Should Know.

Authors:  Petro E Petrides
Journal:  Diagnostics (Basel)       Date:  2022-07-03

7.  Evaluation of Metabolic Changes in Acute Intermittent Porphyria Patients by Targeted Metabolomics.

Authors:  Alex Gomez-Gomez; Paula Aguilera; Klaus Langohr; Gregori Casals; Cristina Pavon; Josep Marcos; Jordi To-Figueras; Oscar J Pozo
Journal:  Int J Mol Sci       Date:  2022-03-16       Impact factor: 5.923

8.  Multiple roles of haem in cystathionine β-synthase activity: implications for hemin and other therapies of acute hepatic porphyria.

Authors:  Abdulla A-B Badawy
Journal:  Biosci Rep       Date:  2021-07-30       Impact factor: 3.840

9.  Acute intermittent porphyria, givosiran, and homocysteine.

Authors:  Antonio Fontanellas; Matías A Ávila; Elena Arranz; Rafael Enríquez de Salamanca; Montserrat Morales-Conejo
Journal:  J Inherit Metab Dis       Date:  2021-06-22       Impact factor: 4.982

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.